Magic Formula Showdown: Why CVS Beats Qualcomm and Valero for Retirees

Photo of Trey Thoelcke
By Trey Thoelcke Published

Quick Read

  • CVS Health leads this Magic Formula ranking for retirees; Valero's forward P/E of 9 tempts but crack spread-driven earnings make income unreliable.

  • Qualcomm's 38% automotive revenue growth and 36% return on equity impress, but its 1.6 beta and 18% monthly share decline disqualify it for retirees.

  • The Magic Formula screens for cheapness and quality, but retirees must layer in dividend stability and low volatility before selecting core portfolio holdings.

  • Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Qualcomm didn't make the cut. Grab the names FREE today.

Magic Formula Showdown: Why CVS Beats Qualcomm and Valero for Retirees

© 24/7 Wall St.

Joel Greenblatt’s Magic Formula, popularized in The Little Book That Beats the Market, ranks stocks on two factors: earnings yield (operating earnings divided by enterprise value) and return on capital (how efficiently a business converts invested dollars into profits). For retirement investors, Magic Formula scores are only the starting point. Income reliability, business durability, and volatility matter equally. A bargain-screened name can still be wrong for a retiree if cash flows swing with commodity cycles or if its multiple assumes growth that may not arrive.

Below is a countdown of three candidates, ranked from least to most appropriate for a retirement-focused portfolio.

3. Qualcomm: Quality at a Quality Price

Qualcomm (NASDAQ: QCOM | QCOM Price Prediction) is the classic Magic Formula quality stock: high gross margins, high returns on equity, and a fortress licensing business. Trailing return on equity is near 36.1%, operating margin around 22.1%, and EV/EBITDA at 14.7. Q2 FY26 delivered non-GAAP EPS of $2.65 on revenue of $10.599 billion, with record Automotive revenue of $1.326 billion, up 38% year over year.

The retirement problem is volatility and yield. Shares fell 16.2% in the past week and 23.9% in the past month, with a beta of 1.596. The dividend yield is just 1.9%, and handset revenue contracted 13% last quarter on memory supply constraints and China exposure. A great business, but not a retiree’s anchor holding.

QCOM analyst ratings
QCOM price target

2. Valero Energy: Cash Machine, Cyclical Risk

Valero Energy (NYSE: VLO) is where the Magic Formula screen lights up brightest. A forward P/E of 9, EV/EBITDA of 8.7, and return on equity of 15.9% combine to signal strong earnings yield and respectable capital efficiency. Q1 2026 EPS hit $4.22 against a $3.16 consensus, refining margins expanded to $14.90 per barrel, and management returned $938 million to shareholders while raising the quarterly dividend 6% to $1.20.

Shares are up 89.4% over the past year. That run is the catch. Refiner earnings swing with crack spreads, the Brent-WTI differential expanded to $5.94 per barrel from $3.43 per barrel, and California exposure produced a $123 million West Coast loss last quarter. The 1.9% yield is well covered, but earnings are not predictable enough for a retiree’s largest position.

VLO analyst ratings
VLO price target

1. CVS Health: The Retiree’s Magic Formula Pick

CVS Health (NYSE: CVS) combines Aetna insurance, the Caremark PBM, and roughly 9,000 retail pharmacies into a defensive, recession-resistant cash-generating enterprise. Forward P/E is just 14, beta is 0.623, and the dividend yields 2.6% on an annualized payout of $2.66. The dividend has been paid quarterly for more than 27 years without interruption.

The turnaround is showing in the numbers. Q1 2026 adjusted EPS came in at $2.57 against a $2.21 estimate, the fourth straight beat, with operating income up 38.71% year over year and Aetna’s adjusted operating income surging 52.6% to $3.04 billion as the medical benefit ratio improved to 84.6%. Management raised full-year adjusted EPS guidance to $7.30 to $7.50 and operating cash flow guidance to at least $9.5 billion. CEO David Joyner described the company as serving “nearly 185 million people” with strong enterprise execution. Shares have climbed 53.1% over the past year to $104.34.

CVS earnings quotes

Risks remain: pharmacy reimbursement pressure, elevated medical cost trends, lingering legacy litigation, and a goodwill-heavy balance sheet from the Aetna deal that drags reported return on capital. Even with those headwinds, the combination of a defensive healthcare footprint, low-beta shares, a multi-decade dividend record, and a forward earnings yield in the low-to-mid teens is the cleanest fit for someone funding retirement withdrawals.

CVS analyst ratings
CVS price target

What This Means for Retirement Portfolios

The Magic Formula is a starting point, not a verdict. Qualcomm offers the best business quality but the thinnest yield and highest volatility. Valero offers the loudest cheapness signal and a generous, growing payout, yet its earnings ride the refining cycle. CVS Health pairs a reasonable multiple with a defensive franchise, an improving Aetna margin story, and a dividend that has weathered every market cycle since the late 1990s. For a retirement investor weighing these three through a Greenblatt lens, CVS best balances cheapness, quality, and the income reliability that funds a withdrawal plan.

 

Photo of Trey Thoelcke
About the Author Trey Thoelcke →

Trey has been an editor and author at 24/7 Wall St. for more than a decade, where he has published thousands of articles analyzing corporate earnings, dividend stocks, short interest, insider buying, private equity, and market trends. His comprehensive coverage spans the full spectrum of financial markets, from blue-chip stalwarts to emerging growth companies.

Beyond 24/7 Wall St., Trey has created and edited financial content for Benzinga and AOL's BloggingStocks, contributing additional hundreds of articles to the investment community. He previously oversaw the 24/7 Climate Insights site, managing editorial operations and content strategy, and currently oversees and creates content for My Investing News.

Trey's editorial expertise extends across multiple publishing environments. He served as production editor at Dearborn Financial Publishing and development editor at Kaplan, where he helped shape financial education materials. Earlier in his career, he worked as a writer-producer at SVE. His freelance editing portfolio includes work for prestigious clients such as Sage Publications, Rand McNally, the Institute for Supply Management, the American Library Association, Eggplant Literary Productions, and Spiegel.

Outside of financial journalism, Trey writes fiction and has been an active member of the writing community for years, overseeing a long-running critique group and moderating workshop sessions at regional conventions. He lives with his family in an old house in the Midwest.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Continue Reading

Top Gaining Stocks

CHTR Vol: 7,405,246
AMAT Vol: 5,099,337
AXON Vol: 741,357
PANW Vol: 3,078,583
GLW Vol: 7,345,861

Top Losing Stocks

HON Vol: 1,789,600
CTRA Vol: 73,319,495
VZ Vol: 22,535,000
MLM Vol: 424,765
TMUS Vol: 2,404,430